Navigation Links
ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver

on with peg-IFN has been completed. Combination therapy including HCV-796 was found to be generally well tolerated. The observed safety profile supports the evaluation of HCV-796 in studies of longer duration.

-- Adverse events across all dose cohorts were generally mild to moderate in severity and were characteristic of the known side effects of interferons.

-- Adverse events that occurred at a frequency of greater than 15 percent across all dose cohorts of HCV-796 plus peg-IFN and peg-IFN alone included headache, chills, myalgias, fever, pain, arthralgia and rash.

-- There were two reports of serious adverse events: one in the placebo arm (pneumonia), and one in the 1000 mg combination cohort (seizure and rhabdomyolysis in a subject receiving high dose methadone chronically).

-- The rate of discontinuation due to adverse events was low across the study. No patient discontinued due to adverse events in the 100, 250, or 500 mg dose cohorts. In the peg-IFN alone group, one patient discontinued due to hypertension; of those that received 1000 mg HCV-796 plus peg-IFN, three patients discontinued due to either vasovagal syncope after a blood draw, rash, or seizure and rhabdomyolysis (in a subject receiving high dose methadone chronically).

-- No dose-limiting toxicities were identified across the range of study doses.

Genetic Sequencing

NS5B sequencing was performed on 36 subjects (11 on peg-IFN alone; 25 HCV- 796 and peg-IFN). Consistent with data from the Phase 1b study of HCV-796 as monotherapy, the only variant of importance detected in patients receiving HCV-796 was a C316Y variant known to have reduced susceptibility to HCV-796. Baseline sequencing did not find any variation from wild type at this position. The C316Y variant was observed in 7 (28 percent) of patients on HCV- 796 plus peg-IFN, occurring less frequently than previously seen in patients receiving HCV-796 as monotherapy, and was not clearly associated w
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:12/15/2009)... Bend Research Inc. announced,today that its clients ... an,excipient used in technologies developed by the firm to ... Bend Research clients may now reference ... regulatory filings with the FDA, Bend Research officials said. ... new development and know it will assist our,clients in ...
(Date:12/15/2009)... LAWRENCE, Mass., Dec. 15 OBP Medical ... comfort and overall patient satisfaction in hospitals. ,, ... measuring the positive effects of OBP Medical,s Under ... hospital stay. A hospital wide survey is comparing ... of their stay while wearing Under Johnnies(TM) against ...
(Date:12/14/2009)... 14 The 2009 Frost & Sullivan ... Market is conferred on SonoScape. The award recipient ... need for special features, pricing, and portability - ... The performance of this high-end colour Doppler HCU ... echo ultrasound system. ,, (Logo: ...
Breaking Medicine Technology:Bend Research Clients May Now Reference Key Safety Document for Important Solubility Excipient 2Under Johnnies(TM) Proven To Increase Patient Satisfaction by OBP Medical Inc. 2Frost & Sullivan Product Quality Leadership Award in the European Ultrasound Market Conferred on SonoScape for S8 2Frost & Sullivan Product Quality Leadership Award in the European Ultrasound Market Conferred on SonoScape for S8 3LCA Announces More Requests for Bids on Lung Cancer Research Programs Funded Through the Department of Defense 53923 1LCA Announces More Requests for Bids on Lung Cancer Research Programs Funded Through the Department of Defense 53923 2Watson Pharmaceuticals and Arrow Group Receive FTC Second Request 53919 1Watson Pharmaceuticals and Arrow Group Receive FTC Second Request 53919 2United Cargo Launches Temp Control Service 53915 1United Cargo Launches Temp Control Service 53915 2
... SUNNYVALE, Calif. and LOS ANGELES, April 18, ... two preclinical studies, one identifying a functional,biomarker ... and,another demonstrating preclinical anti-tumor activity with its,Bruton's ... were,presented at the American Association for Cancer ...
... 2007 - EPIX,Pharmaceuticals, Inc. (NASDAQ: EPIX) ... its Phase 1b multiple ascending,dose clinical ... 5-HT6 antagonist being developed for,obesity, Alzheimer's ... The randomized, double-blind, placebo-controlled Phase 1b,multiple ...
Other Medicine Technology:Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 2Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 3Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 4Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC,Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with,Bruton's Tyrosine Kinase Inhibitors 5EPIX Pharmaceuticals Announces Statistically Significant Results in,Cognitive Function from Phase 1b Clinical Trial of Novel 5-HT6 Drug,Candidate 2EPIX Pharmaceuticals Announces Statistically Significant Results in,Cognitive Function from Phase 1b Clinical Trial of Novel 5-HT6 Drug,Candidate 3EPIX Pharmaceuticals Announces Statistically Significant Results in,Cognitive Function from Phase 1b Clinical Trial of Novel 5-HT6 Drug,Candidate 4
(Date:12/15/2009)... will they get paid for patient care? Capture,s medical billing ... ... Washington, DC (Vocus) December 15, 2009 ... These codes are what healthcare providers submit to Medicare ... consultation, whether in a provider’s office or hospital setting. Healthcare ...
(Date:12/15/2009)... named 4th Best Staffing Firm to Work For. , ... ... has named LocumTenens.com, a leading provider of temporary physician and CRNA ... their inaugural 2009 list., , , , ,“We are proud to ... care about investing in our associates,” said R. Shane Jackson president ...
(Date:12/15/2009)... out-of-pocket costs for beneficiaries based on health status categories and ... ... Antonio, TX (Vocus) Dec. 14, 2009 -- Physicians Health Choice ... recognized for cost-sharing effectiveness and value in the design of ... Medicare beneficiaries. The Medicare Advantage company won for its ...
(Date:12/15/2009)... most caring, conscientious practice you have ever been a part of. ... Dallas, we can help to achieve this goal and meet your ... ... -- The Dermatology Center of Dallas, a Dallas based, full-service medical ... “J.B.” Foshee, MD in their practice. Dr. Foshee joins James ...
(Date:12/15/2009)... - 2009 Industry trend Continues as Henry Ford Health System ... (SaaS) provider- , ... Hazlet, ... provider of Software-as-a-Service (SaaS) talent acquisition solutions , announced ... iCIMS Talent Platform to support its talent management needs. ...
Breaking Medicine News(10 mins):Health News:Medicare Eliminates Consultation Codes for Doctors 2Health News:LocumTenens.com Named 4th Best Staffing Firm to Work For 2Health News:Physicians Health Choice Receives Senior Choice Gold Award for 2010 Medicare Plan Benefits 2Health News:Physicians Health Choice Receives Senior Choice Gold Award for 2010 Medicare Plan Benefits 3Health News:Physicians Health Choice Receives Senior Choice Gold Award for 2010 Medicare Plan Benefits 4Health News:Jeri Beth “J.B.” Foshee, MD Joins Dermatology Center of Dallas 2Health News:iCIMS Emerges as Talent Management Solution of Choice for Henry Ford Health Systems 2Health News:iCIMS Emerges as Talent Management Solution of Choice for Henry Ford Health Systems 3Health News:iCIMS Emerges as Talent Management Solution of Choice for Henry Ford Health Systems 4
... that underlie sporadic amyotrophic lateral sclerosis (ALS), the most ... hurdle with the// successful compiling of genetic information on ... the study, supported by The Packard Center for ALS ... Disorders and Stroke (NINDS) and the ALS Association, present ...
... the US Department of Labor some of the hottest ... field abound for men and women alike.// ... often elect to become a medical assistant via accelerated ... training institutions.Although the medical assisting curriculum is broad and ...
... pain syndrome that affects 2 to 4 percent of ... the condition is real.// ,Fibromyalgia often has ... Increasingly, though, the scientific knowledge about fibromyalgia is growing, ... Health System says there are “overwhelming data” that the ...
... issued an alert in six provinces to step up vigilance ... to the agriculture ministry.// ,South Korea Tuesday reported ... as pigs and dogs culled. ,Heilongjiang, Jilin, Liaoning, ... South Korea. ,The agriculture ministry said the outbreak ...
... New Delhi and in Mumbai suffers from backache, caused mainly ... // ,Carried out by Health India, a New Delhi-based ... people in New Delhi and 77 percent in Mumbai who ... back problems. ,"Bad roads, overcrowded public transport systems, ...
... is a new system developed by UK Hospitals, which enables ... premature neonates on time. The// system aims to speed up ... saving lives of many. ,Previously in the case of ... a cot, which delayed the treatment process. But with the ...
Other Medicine News:Health News:First International Gene Screen for Typical ALS Is on Track 2Health News:Guiding Students Toward a Successful Medical Assistant Career 2Health News:Guiding Students Toward a Successful Medical Assistant Career 3Health News:The Pain from Fibromyalgia Is Real, Researchers Say 2Health News:Public Transport Causing Backaches in Delhi, Mumbai 2
Ideal for abdominal procedures...
... one-of-kind Expander Sizer™ is ... problem of achieving the ... Expander Sizer™ zipper system ... to post procedure swelling ...
For lipoplasty of trochanteric area, abdomen, thighs, hips, buttocks and flanks...
Black Spandex Above the Knee Compression Girdles with Contact Closure with Zipper...
Medicine Products: